Evidence map›Paper›PMID 39473305›Full record

ArticleEuropean journal of heart failure2025

Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.

Yogesh N V Reddy, Javed Butler, Kevin J Anstrom, Robert O Blaustein, Marc P Bonaca, Stefano Corda, Justin A Ezekowitz, Carolyn S P Lam, Eldrin F Lewis, JoAnn Lindenfeld and 11 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05093933 (A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05093933 phase3completednot on this map

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2021 to 2025Enrolled6,106ConditionsChronic Heart Failure With Reduced Ejection FractionArmsVericiguat, Placebo
3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Use of vericiguat in the VICTOR trial: a study that is difficult to interpret.European heart journal supplements : journal of the European Society of Cardiology · 2026
    Article
  8. Vericiguat: A New Horizon for Heart Failure Treatment.Reviews in cardiovascular medicine · 2026
    Review
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yogesh N V ReddyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX, USA.
Kevin J AnstromUniversity of North Carolina, Chapel Hill, NC, USA.
Robert O BlausteinMerck & Co., Inc., Rahway, NJ, USA.
Marc P BonacaColorado Prevention Center Clinical Research, Department of Medicine, University of Colorado, Aurora, CO, USA.
Stefano CordaBayer AG, Wuppertal, Germany.
Justin A EzekowitzCanadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Carolyn S P LamNational Heart Centre Singapore and Duke-National University, Singapore, Singapore.
Eldrin F LewisStanford University School of Medicine Stanford, Stanford, CA, USA.
JoAnn LindenfeldVanderbilt University Medical Center, Nashville, TN, USA.
Ciaran J McMullanMerck & Co., Inc., Rahway, NJ, USA.
Robert J MentzDuke Clinical Research Institute, Durham, NC, USA.
Christopher O'ConnorInova Heart and Vascular Institute, Falls Church, VA, USA.
Mahesh PatelMerck & Co., Inc., Rahway, NJ, USA.
Piotr PonikowskiWroclaw Medical University, Wroclaw, Poland.
Giuseppe M C RosanoSt George's Hospital Medical School, London, UK.
Clara I SaldarriagaCardio VID Clinic, Medellin, Colombia.
Michele SenniPapa Giovanni XXIII Hospital, Bergamo, Italy.
James UdelsonTufts Medical Center, Boston, MA, USA.
Adriaan A VoorsGroningen Heart Failure Research Institute, Groningen, The Netherlands.
Faiez ZannadCVCT and Universite de Lorraine, Nancy, France.

Funding

Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle TrainingK23HL164901 · MAYO CLINIC ROCHESTER · 2025 to 2025
$168k
Bayer AG, Wuppertal, GermanyMerck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USANHLBI NIH HHS K23 HL164901
6 · The paper itself

Abstract

aimsIn the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy.

methodsThe primary endpoint for VICTOR is time to first event for the composite of HHF or cardiovascular death. The trial will also assess the effect of vericiguat on time to cardiovascular death, time to HHF, total HHF, and all-cause death. As an event-driven trial, at least 1080 primary events are expected, but follow-up will continue until the targeted number of at least 590 cardiovascular deaths has been reached. Approximately 6000 participants will be randomized to vericiguat or placebo.

conclusionVICTOR is the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational guideline-directed medical therapy, in a compensated ambulatory HF population. VICTOR will add important information to the evidence of the effects of vericiguat across the spectrum of patients with HFrEF.

Indexed as

Heart FailureHeterocyclic Compounds, 2-RingPyrimidinesStroke VolumeChronic DiseaseFemaleHospitalizationHumansMaleRandomized Controlled Trials as TopicTreatment OutcomeHeterocyclic Compounds, 2-RingPyrimidinesvericiguatHeart failure with reduced ejection fractionVericiguat

Identifiers

PMID39473305
PMCPMC11860724

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.